This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Cerevel Therapeutics Holdings Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Cerevel Therapeutics Holdings's earnings have been declining at an average annual rate of -30.8%, while the Biotechs industry saw earnings growing at 16.1% annually.
Belangrijke informatie
-30.8%
Groei van de winst
-3.6%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | n/a |
| Rendement op eigen vermogen | -81.6% |
| Nettomarge | n/a |
| Laatste winstupdate | 31 Mar 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?
Apr 30
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jan 02Cerevel overweight at Wells Fargo due to candidates with blockbuster potential
Sep 26Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering
Aug 12Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13
Aug 01Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded
Jul 08Cerevel Therapeutics: Pfizer's Neurology Spin-Off
Jul 14We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate
Jun 09Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?
Jan 29Cerevel Therapeutics (CERE) Investor Presentation - Slideshow
Nov 18Cerevel Therapeutics reports Q3 results
Nov 16Opbrengsten en kosten
Hoe Cerevel Therapeutics Holdings geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -460 | 127 | 363 |
| 31 Dec 23 | 0 | -433 | 113 | 335 |
| 30 Sep 23 | 0 | -393 | 96 | 319 |
| 30 Jun 23 | 0 | -397 | 94 | 305 |
| 31 Mar 23 | 0 | -388 | 91 | 303 |
| 31 Dec 22 | 0 | -352 | 88 | 280 |
| 30 Sep 22 | 0 | -318 | 78 | 247 |
| 30 Jun 22 | 0 | -280 | 69 | 216 |
| 31 Mar 22 | 0 | -243 | 61 | 180 |
| 31 Dec 21 | 0 | -225 | 58 | 162 |
| 30 Sep 21 | 0 | -196 | 45 | 144 |
| 30 Jun 21 | 0 | -173 | 44 | 128 |
| 31 Mar 21 | 0 | -146 | 41 | 113 |
| 31 Dec 20 | 0 | -148 | 40 | 103 |
| 30 Sep 20 | 0 | -175 | 48 | 95 |
| 30 Jun 20 | 0 | -172 | 45 | 88 |
| 31 Mar 20 | 0 | -151 | 40 | 73 |
| 31 Dec 19 | 0 | -128 | 33 | 50 |
Kwaliteitswinsten: CERE is currently unprofitable.
Groeiende winstmarge: CERE is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: CERE is unprofitable, and losses have increased over the past 5 years at a rate of 30.8% per year.
Versnelling van de groei: Unable to compare CERE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: CERE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-34.5%).
Rendement op eigen vermogen
Hoge ROE: CERE has a negative Return on Equity (-81.58%), as it is currently unprofitable.